CA3216131A1 - Canine monoclonal antibodies against canine cytotoxic t lymphocyte associated protein 4 (ctla-4) - Google Patents

Canine monoclonal antibodies against canine cytotoxic t lymphocyte associated protein 4 (ctla-4) Download PDF

Info

Publication number
CA3216131A1
CA3216131A1 CA3216131A CA3216131A CA3216131A1 CA 3216131 A1 CA3216131 A1 CA 3216131A1 CA 3216131 A CA3216131 A CA 3216131A CA 3216131 A CA3216131 A CA 3216131A CA 3216131 A1 CA3216131 A1 CA 3216131A1
Authority
CA
Canada
Prior art keywords
seq
amino acid
acid sequence
chain variable
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3216131A
Other languages
English (en)
French (fr)
Inventor
Nicola J. MASON
Donald L. Siegel
Nicholas CHESTER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vetigenics LLC
University of Pennsylvania Penn
Original Assignee
Vetigenics LLC
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vetigenics LLC, University of Pennsylvania Penn filed Critical Vetigenics LLC
Publication of CA3216131A1 publication Critical patent/CA3216131A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3216131A 2021-04-21 2022-04-20 Canine monoclonal antibodies against canine cytotoxic t lymphocyte associated protein 4 (ctla-4) Pending CA3216131A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163177692P 2021-04-21 2021-04-21
US63/177,692 2021-04-21
PCT/US2022/025614 WO2022226102A1 (en) 2021-04-21 2022-04-20 Canine monoclonal antibodies against canine cytotoxic t lymphocyte associated protein 4 (ctla-4)

Publications (1)

Publication Number Publication Date
CA3216131A1 true CA3216131A1 (en) 2022-10-27

Family

ID=83723402

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3216131A Pending CA3216131A1 (en) 2021-04-21 2022-04-20 Canine monoclonal antibodies against canine cytotoxic t lymphocyte associated protein 4 (ctla-4)

Country Status (5)

Country Link
US (2) US12110331B2 (https=)
EP (1) EP4326324A4 (https=)
JP (1) JP2024516621A (https=)
CA (1) CA3216131A1 (https=)
WO (1) WO2022226102A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240109967A1 (en) * 2021-04-21 2024-04-04 The Trustees Of The University Of Pennsylvania Canine monoclonal antibodies against canine cytotoxic t lymphocyte associated protein 4 (ctla-4)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240358834A1 (en) * 2023-04-28 2024-10-31 The Trustees Of The University Of Pennsylvania Novel cd19-targeting polypeptides and cd19-directed immunotherapies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA314534A (en) * 1931-08-25 The United States Gypsum Company Roof or floor
US7261890B2 (en) * 2001-12-21 2007-08-28 Idexx Laboratories, Inc. Methods for using canine immunoglobulin variable domains and caninized antibodies
US8722587B2 (en) * 2008-04-09 2014-05-13 The Trustees Of The University Of Pennsylvania Single chain fragment variable antibody libraries and uses thereof
CA3145345A1 (en) * 2019-07-15 2021-01-21 Intervet International B.V. Caninized antibodies against canine ctla-4
CA3216131A1 (en) * 2021-04-21 2022-10-27 Nicola J. MASON Canine monoclonal antibodies against canine cytotoxic t lymphocyte associated protein 4 (ctla-4)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240109967A1 (en) * 2021-04-21 2024-04-04 The Trustees Of The University Of Pennsylvania Canine monoclonal antibodies against canine cytotoxic t lymphocyte associated protein 4 (ctla-4)
US12110331B2 (en) * 2021-04-21 2024-10-08 The Trustees Of The University Of Pennsylvania Canine monoclonal antibodies against canine cytotoxic T lymphocyte associated protein 4 (CTLA-4)

Also Published As

Publication number Publication date
WO2022226102A1 (en) 2022-10-27
JP2024516621A (ja) 2024-04-16
EP4326324A1 (en) 2024-02-28
US20240109967A1 (en) 2024-04-04
US20250171541A1 (en) 2025-05-29
US12110331B2 (en) 2024-10-08
EP4326324A4 (en) 2026-03-25

Similar Documents

Publication Publication Date Title
TWI800506B (zh) 免疫結合物
JP7791229B2 (ja) 抗体
US20220025046A1 (en) Bispecific antigen binding molecules targeting ox40 and fap
CN114805582B (zh) 抗Trop2纳米抗体及其用途
CN114761036B (zh) 与小鼠和人成纤维细胞激活蛋白(fap)交叉反应的抗犬成纤维细胞激活蛋白单克隆抗体
KR20200139189A (ko) 다가 항체
US20250171541A1 (en) Canine monoclonal antibodies against canine cytotoxic t lymphocyte associated protein 4 (ctla-4)
CN116496396B (zh) 抗cd70纳米抗体及其用途
JP2023543493A (ja) ヒトクローディン１８．２を標的とする抗体及びその使用
US20230192861A1 (en) Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof
JP2021505137A (ja) 悪性ｂ細胞を特異的に認知する抗体またはその抗原結合断片、これを含むキメラ抗原受容体及びその用途
WO2023108138A9 (en) Fully canine anti-canine pd-1 antibodies and uses thereof
CN114685659B (zh) Cd22特异性人源化抗体及利用其的嵌合抗原受体
WO2023241493A1 (zh) 一种特异性结合Trop2的抗体或其抗原结合片段及其制备方法和应用
CN117264055A (zh) 一种特异性结合人cd318的vhh抗体或其抗原结合片段及其制备方法和应用
WO2025113570A1 (en) Fully canine antibodies and uses thereof
TWI894360B (zh) 抗tigit抗體及雙抗體和它們的應用
CN118496368B (zh) Trop2抗体或其抗原结合片段及其应用
CA3107192C (en) Antibody constructs for cldn18.2 and cd3
CN121378490A (zh) Trop2抗体或其抗原结合片段及其应用
CN117460745A (zh) 抗gpc3和抗cd137多特异性抗体及使用方法
HK40071804A (zh) 与小鼠和人成纤维细胞激活蛋白(fap)交叉反应的抗犬成纤维细胞激活蛋白单克隆抗体
HK1236976B (en) Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250407

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250407

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260417

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260417

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260417

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260420

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260420

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260423

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260423

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260423

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260423

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260423

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260423